Research progress on dynamic monitoring of ctDNA and drug resistance related concomitant mutations in non-small cell lung cancer
Owing to significantly prolonged survival,targeted therapy has become standardized recommendation for ad-vanced non-small cell lung cancer patients with mutated driver genes.However,the genetic status of lung cancer patients is dynam-ic.By dynamically monitoring the evolution of genes status,differential genes and concomitant genes related to progressive disease could be confirmed early,so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients.Under the guidance of accurate genetic testing results,it is helpful to provide patients with more effective,long-term,and stable individualized targeted therapy.
国家科技期刊平台
NSTL
万方数据
维普
